Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health (GH) director Manuel Hidalgo Medina reported the vesting and settlement of restricted stock units into 232 shares of Common Stock on 10/17/2025 (transaction code M) at $0 per share.
Following the transaction, he directly owned 1,315 shares of Common Stock and held 7,657 RSUs outstanding. The RSU grant dated July 17, 2024 vests over four years: 25% vested on the one-year anniversary of July 17, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) reported an insider transaction on a Form 4. A company director sold 116 shares of common stock at $66.95 on 10/17/2025. Following the sale, the reporting person directly holds 7,725 shares.
Guardant Health (GH) filed a Form 4 disclosing an insider sale. Director Myrtle S. Potter sold 26 shares of common stock on 10/17/2025 at $66.95 per share. After this transaction, she directly beneficially owns 18,324 shares. The filing lists the ownership form as direct and does not report any derivative security activity.
Guardant Health (GH) reported an insider equity change by a director. On October 15, 2025, 69 shares of Common Stock were acquired at $0 upon the vesting and settlement of Restricted Stock Units (RSUs) (transaction code M). Following this, the director directly owned 18,350 shares.
The RSU award vested 25% on October 15, 2022, with the remaining 75% vesting in substantially equal monthly installments over the next three years.
Guardant Health (GH) director reports Form 4 activity. On 10/15/2025, 250 shares of common stock were acquired at $0 following the settlement of restricted stock units (transaction code M). After this transaction, the reporting person directly owns 7,841 shares.
The related derivative line shows 250 restricted stock units converted into 250 shares at $0 on 10/15/2025, leaving 4,248 derivative securities (restricted stock units) directly beneficially owned after the event.
The award referenced in the footnotes was granted on March 6, 2023 and vests over four years: 25% vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the following three years.
Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported multiple equity transactions dated 10/01/2025. He had 13,550 restricted stock units vest or be credited (1,928; 1,668; 9,954) and a separate purchase of 5,740 shares at $62.65. The company retained 5,740 shares to satisfy the tax withholding related to one vesting installment; the filer notes the retained amount did not exceed the tax liability. Following the reported transactions, Freeman beneficially owned 63,179 shares (direct ownership). The Form 4 was signed by an attorney-in-fact on behalf of Mr. Freeman on 10/02/2025.
Guardant Health director and Co‑Chief Executive Officer AmirAli Talasaz reported multiple transactions in the company's common stock. On 09/30/2025 he received 4,814 shares from vesting of restricted stock units and, separately the same day, 2,440 shares were retained by the company to satisfy tax withholding at a reported price of $62.48. On 10/01/2025 he received an additional 23,997 vested shares and 12,162 shares were retained for tax withholding at $62.65. After these reported transactions his beneficial ownership rose to 2,010,036 shares.
Steve E. Krognes, a director of Guardant Health, Inc. (GH), reported a transaction dated 09/30/2025 in which 154 shares were acquired following vesting of restricted stock units. The Form 4 shows the acquisition price as $0, reflecting conversion of vested RSUs into common stock. After the transaction, the filing reports 18,282 shares of common stock beneficially owned by Mr. Krognes and 1,389 RSU-linked derivative shares reported as beneficially owned. The RSU award was originally granted on 08/09/2022 and vested 25% on 06/30/2023, with the remaining 75% vesting in substantially equal monthly installments over the following three years. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Krognes on 10/02/2025.
Helmy Eltoukhy, Co-Chief Executive Officer and director of Guardant Health (GH), reported multiple transactions on 09/30/2025 and 10/01/2025. He had restricted stock units vest that resulted in acquisitions of 4,814 and 23,997 shares (reported as acquisitions at $0), with the company retaining 2,440 and 12,162 shares respectively to satisfy tax-withholding obligations related to the vesting (sales at $62.48 and $62.65). After the reported activity, his beneficial ownership of common stock is shown as 2,149,870 shares following the 10/01/2025 transactions and 119,986 RSU-equivalent shares remaining reported as derivative holdings. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Eltoukhy.
Insider awards to Guardant Health director Alex M. Azar II
Alex M. Azar II, identified as a director of Guardant Health (GH), received equity awards on 09/12/2025. The filing reports a stock option to purchase 10,532 shares with an exercise price of $54.895 and an option term through 09/12/2035. The option and a separate restricted stock unit (RSU) award for 6,604 shares both vest over four years (25% one year after grant, remainder monthly over three years). The Form 4 was signed by an attorney-in-fact on 09/26/2025. The filing shows direct beneficial ownership following the grants: 10,532 option shares and 6,604 RSU shares.